Endogenous intracellular allosteric modulators of GPCRs remain largely unexplored, with limited binding and phenotype data available. This gap arises from the lack of robust computational methods for ...

With as much as $17 billion in sales in 2024, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). This Scandinavian economic behemoth ...

Novo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down as competition in the weight-loss drug space pressured the company's stock. "Considering the recent market challenges, the share price ...

Novo Nordisk, the maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by "mutual agreement" with the company's board of directors, citing "recent market challenges ...

LONDON (Reuters) - Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive ...

Under Jorgensen's leadership, Novo Nordisk became a world leader in the lucrative weight-loss drug market, with sky-rocketing sales of its Wegovy and Ozempic treatments. Sign up here. "The changes ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug ...

Novo Nordisk A/S announced its Q1 earnings today, blaming a slight revenue miss on sales of compounded semaglutide. Q1 2025 earnings showed revenue of ~$11.9bn, operating profit of $5.9bn, with ...